Objective IgG antibodies against apolipoprotein A‐I (ApoA‐I) have been found to be
elevated in subjects from the general population with clinically manifest cardiovascular …

We aimed to determine the association between autoantibodies against apolipoprotein A-1
(anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of …

Abstract Objective Anti-Apolipoprotein A-1 autoantibodies (anti-ApoA-1 IgG) represent an
emerging prognostic cardiovascular marker in patients with myocardial infarction or …

Abstract Aims Anti-Apolipoprotein A-1 auto-antibodies (anti-ApoA-1 IgG) represent an
emerging prognostic cardiovascular marker in patients with myocardial infarction or …

Background Autoantibodies against apolipoprotein A1 (anti-apoA1 IgG) have emerged as
an independent biomarker for cardiovascular disease and mortality. Across studies, different …

Immune-driven inflammation plays an important part in atherogenesis and is therefore
believed to be key to the development of cardiovascular disease (CVD), which is currently …

Background Autoantibodies to apolipoprotein A‐1 (anti‐ApoA‐1 IgG) were shown to predict
major adverse cardiovascular events and promote atherogenesis. However, their potential …

Objective: The immune response is linked to the progression of atherosclerotic
cardiovascular disease (CVD). Free autoantibodies targeting ApoA-I (apolipoprotein AI) …

Immune‐mediated inflammation plays a major role in atherosclerosis and atherothrombosis,
two essential features for cardiovascular disease (CVD) development, currently considered …

We aimed at determining whether anti‐apolipoprotein (apo) A‐1 IgG levels are independent
predictors of coronary artery calcification (CAC) and coronary endothelial dysfunction in …